JPWO2022195028A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022195028A5 JPWO2022195028A5 JP2023556501A JP2023556501A JPWO2022195028A5 JP WO2022195028 A5 JPWO2022195028 A5 JP WO2022195028A5 JP 2023556501 A JP2023556501 A JP 2023556501A JP 2023556501 A JP2023556501 A JP 2023556501A JP WO2022195028 A5 JPWO2022195028 A5 JP WO2022195028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- binding molecule
- ccr9
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 46
- 102100036303 C-C chemokine receptor type 9 Human genes 0.000 claims description 38
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 26
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 239000012642 immune effector Substances 0.000 claims description 9
- 229940121354 immunomodulator Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 102100021933 C-C motif chemokine 25 Human genes 0.000 claims description 8
- 102000004900 CC chemokine receptor 9 Human genes 0.000 claims description 8
- 108090001026 CC chemokine receptor 9 Proteins 0.000 claims description 8
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 239000012636 effector Substances 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 102000009490 IgG Receptors Human genes 0.000 claims description 4
- 108010073807 IgG Receptors Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 2
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000033300 receptor internalization Effects 0.000 claims description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 37
- 238000000034 method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 208000011231 Crohn disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024180571A JP2025011259A (ja) | 2021-03-18 | 2024-10-16 | 治療用結合分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162603P | 2021-03-18 | 2021-03-18 | |
| US63/162,603 | 2021-03-18 | ||
| PCT/EP2022/057029 WO2022195028A2 (en) | 2021-03-18 | 2022-03-17 | Therapeutic binding molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024180571A Division JP2025011259A (ja) | 2021-03-18 | 2024-10-16 | 治療用結合分子 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2024516769A JP2024516769A (ja) | 2024-04-17 |
| JP2024516769A5 JP2024516769A5 (https=) | 2024-05-23 |
| JPWO2022195028A5 true JPWO2022195028A5 (https=) | 2024-05-23 |
| JP7574467B2 JP7574467B2 (ja) | 2024-10-28 |
Family
ID=81327268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556501A Active JP7574467B2 (ja) | 2021-03-18 | 2022-03-17 | 治療用結合分子 |
| JP2024180571A Pending JP2025011259A (ja) | 2021-03-18 | 2024-10-16 | 治療用結合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024180571A Pending JP2025011259A (ja) | 2021-03-18 | 2024-10-16 | 治療用結合分子 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12049506B2 (https=) |
| EP (2) | EP4308607A2 (https=) |
| JP (2) | JP7574467B2 (https=) |
| KR (2) | KR20250069981A (https=) |
| CN (1) | CN116997571A (https=) |
| AR (1) | AR125142A1 (https=) |
| AU (2) | AU2022236492B2 (https=) |
| CA (1) | CA3212630A1 (https=) |
| CL (1) | CL2023002759A1 (https=) |
| CO (1) | CO2023013566A2 (https=) |
| CR (1) | CR20230488A (https=) |
| EC (1) | ECSP23078844A (https=) |
| IL (2) | IL305690B2 (https=) |
| MA (1) | MA71643A (https=) |
| MX (1) | MX2023010917A (https=) |
| NZ (1) | NZ804536A (https=) |
| TW (1) | TWI872319B (https=) |
| WO (1) | WO2022195028A2 (https=) |
| ZA (1) | ZA202309418B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53338A (fr) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica Nv | Dosages pour détecter la neurodégénérescence |
| EP4417623A1 (en) * | 2023-02-15 | 2024-08-21 | Fundació Institut de Recerca Contra la Leucèmia Josep Carreras | Ccr9 targeting moiety for the treatment of ccr9-positive cancer |
| EP4578874A1 (en) | 2023-12-29 | 2025-07-02 | SunRock Biopharma S.L. | Anti-ccr9 antibody |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6696248B1 (en) | 1995-08-18 | 2004-02-24 | Morphosys Ag | Protein/(poly)peptide libraries |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6329159B1 (en) * | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| ATE482275T1 (de) | 1999-07-02 | 2010-10-15 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| BR0316101A (pt) | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| EP2876114A1 (en) * | 2013-11-25 | 2015-05-27 | Consejo Superior De Investigaciones Científicas | Antibodies against CCR9 and applications thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2022
- 2022-03-17 MX MX2023010917A patent/MX2023010917A/es unknown
- 2022-03-17 KR KR1020257014756A patent/KR20250069981A/ko active Pending
- 2022-03-17 CN CN202280021611.7A patent/CN116997571A/zh active Pending
- 2022-03-17 US US17/697,041 patent/US12049506B2/en active Active
- 2022-03-17 CR CR20230488A patent/CR20230488A/es unknown
- 2022-03-17 KR KR1020237034201A patent/KR102805310B1/ko active Active
- 2022-03-17 NZ NZ804536A patent/NZ804536A/en unknown
- 2022-03-17 IL IL305690A patent/IL305690B2/en unknown
- 2022-03-17 EP EP22716861.4A patent/EP4308607A2/en active Pending
- 2022-03-17 MA MA71643A patent/MA71643A/fr unknown
- 2022-03-17 AU AU2022236492A patent/AU2022236492B2/en active Active
- 2022-03-17 JP JP2023556501A patent/JP7574467B2/ja active Active
- 2022-03-17 WO PCT/EP2022/057029 patent/WO2022195028A2/en not_active Ceased
- 2022-03-17 IL IL318237A patent/IL318237A/en unknown
- 2022-03-17 US US18/550,757 patent/US20240174758A1/en active Pending
- 2022-03-17 EP EP24154419.6A patent/EP4406592A3/en active Pending
- 2022-03-17 CA CA3212630A patent/CA3212630A1/en active Pending
- 2022-03-18 AR ARP220100634A patent/AR125142A1/es unknown
- 2022-03-18 TW TW111110226A patent/TWI872319B/zh active
-
2023
- 2023-09-15 CL CL2023002759A patent/CL2023002759A1/es unknown
- 2023-10-09 ZA ZA2023/09418A patent/ZA202309418B/en unknown
- 2023-10-13 CO CONC2023/0013566A patent/CO2023013566A2/es unknown
- 2023-10-17 EC ECSENADI202378844A patent/ECSP23078844A/es unknown
-
2024
- 2024-07-29 US US18/787,823 patent/US20250084174A1/en active Pending
- 2024-10-16 JP JP2024180571A patent/JP2025011259A/ja active Pending
-
2025
- 2025-07-03 AU AU2025205131A patent/AU2025205131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109071664B (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| JP2025011259A5 (https=) | ||
| JP7397882B2 (ja) | 二重特異性抗体及びその調製方法、使用 | |
| JP6181043B2 (ja) | 抗神経成長因子抗体ならびにそれを調製および使用する方法 | |
| JP7355977B2 (ja) | Ｃｄ２４に結合する抗体、その調製および使用 | |
| AU2019229676A1 (en) | PD1 binding agents | |
| CN110300764A (zh) | 抗SIRPg抗体的新用途 | |
| CA2778864A1 (en) | Humanized antibodies against human il-22ra | |
| CN115785272A (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| US20140294815A1 (en) | Caninised tumour necrosis factor antibodies and methods of using the same | |
| TW202305006A (zh) | 與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體 | |
| EP3856778A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| WO2023118395A1 (en) | Treatment paradigm for an anti-cd19 antibody therapy | |
| PT2171060E (pt) | Anticorpo anti-cd28 superagonista | |
| CN106164094A (zh) | 双特异性抗原结合多肽 | |
| TW202307004A (zh) | 抗ｃｅａ抗體及使用方法 | |
| JPWO2022195028A5 (https=) | ||
| JP7837873B2 (ja) | ヒト化抗ＴｒｋＡ抗体及びその使用 | |
| WO2023110937A1 (en) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling | |
| US20230242640A1 (en) | ANTI-SIRPg Compounds | |
| US12606617B2 (en) | Composition comprising an IgE antibody | |
| RU2833233C2 (ru) | Антитела к хелатным радионуклидам | |
| JPWO2023138551A5 (https=) | ||
| WO2024044675A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies | |
| TW201321406A (zh) | 腫瘤壞死因子抗體及使用其之方法 |